Capital International (RPRX) amendment shows 8.8% stake in Royalty Pharma

Rhea-AI Filing Summary

Royalty Pharma PLC disclosure: Capital International Investors reports beneficial ownership of 37,772,419 shares, representing 8.8% of the 428,418,612 shares believed to be outstanding. The filing is an Amendment No. 3 to a Schedule 13G/A and is signed on 05/13/2026.

The filing states CII has sole power to vote on 37,448,042 shares and sole dispositive power over 37,772,419 shares. The disclosure names the investment management entities that make up Capital International Investors.

Insights

Institutional Ownership Analyst

Large passive holding disclosed: 8.8% stake reported by Capital International Investors.

Capital International Investors reports beneficial ownership of 37,772,419 shares, or 8.8%, of Royalty Pharma's common stock, per the Schedule 13G/A amendment.

This filing documents ownership and voting/dispositive powers held through Capital's investment management entities; cash‑flow treatment and sale intent are not stated in the excerpt. Subsequent filings may disclose changes in position.

Key Figures

Shares beneficially owned: 37,772,419 shares Percent of class: 8.8% Shares outstanding (believed): 428,418,612 shares +1 more

4 metrics

Shares beneficially owned 37,772,419 shares reported ownership

Percent of class 8.8% of 428,418,612 shares believed outstanding

Shares outstanding (believed) 428,418,612 shares shares believed to be outstanding

Sole power to vote 37,448,042 shares reported voting power

Key Terms

Schedule 13G/A, beneficially owned, sole dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 3 to Schedule 13G/A discloses beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"CII is deemed to be the beneficial owner of 37,772,419 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 37,772,419"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 12:52 PM Learn about SEC filing dates

FAQ

What stake does Capital International Investors report in Royalty Pharma (RPRX)?

Capital International Investors reports beneficial ownership of 37,772,419 shares representing 8.8% of Royalty Pharma's common stock. The filing cites a total of 428,418,612 shares believed to be outstanding and is signed on 05/13/2026.

Does Capital International Investors have voting control over its Royalty Pharma shares?

The filing states CII has sole power to vote 37,448,042 shares. It also reports sole dispositive power over 37,772,419 shares, indicating voting and disposition authority through its management entities.

Which entities are included under Capital International Investors in this filing?

The disclosure lists CRMC and its investment management subsidiaries including Capital Bank and Trust Company, Capital International, Inc., and others collectively providing services under the name Capital International Investors.

Is this a new purchase or a passive reporting filing?

This document is an Amendment No. 3 to a Schedule 13G/A, a form commonly used for passive investors to disclose holdings. The filing describes ownership but does not state purchase timing or intent to trade.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Royalty Pharma PLC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

G7709Q104

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): G7709Q104

1

Names of Reporting Persons

Capital International Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 37,448,042.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 37,772,419.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

37,772,419.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.8 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Royalty Pharma PLC
(b)	Address of issuer's principal executive offices: 110 EAST 59TH STREET, NEW YORK, NY 10022
Item 2.
(a)	Name of person filing: Capital International Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: G7709Q104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 37,772,419 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 37,772,419 shares or 8.8% of the 428,418,612 shares believed to be outstanding.
(b)	Percent of class: 8.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 37,448,042
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 37,772,419
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital International Investors

Signature:	Aaron Espin
Name/Title:	Senior Vice President
Date:	05/13/2026